Related Experiment Videos

Peripheral blood and bone marrow findings in patients with acquired immune deficiency syndrome

C E Harris1, J C Biggs, A J Concannon

  • 1Department of Hematology, St. Vincent's Hospital, Sydney.

Pathology
|October 1, 1990
PubMed

Insights

Bone marrow examinations in human immunodeficiency virus (HIV) patients revealed specific findings like opportunistic infections and malignancy in one-third of cases. Non-specific abnormalities were common, with AZT therapy potentially worsening blood and bone marrow issues.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Oncology

Background:

  • Human immunodeficiency virus (HIV) infection significantly impacts the hematopoietic system.
  • Bone marrow examination is a crucial diagnostic tool for staging and understanding disease progression in HIV/AIDS patients.

Purpose of the Study:

  • To evaluate the diagnostic yield of bone marrow examinations in HIV-positive patients.
  • To identify specific and non-specific hematological abnormalities in HIV/AIDS patients.
  • To assess the impact of antiretroviral therapy (AZT) on bone marrow findings.

Main Methods:

  • Retrospective analysis of 183 bone marrow examinations from 155 HIV-positive patients (1984-1987).
  • Categorization of findings into specific (infections, malignancies, ITP, iron deficiency) and non-specific abnormalities.
  • Inclusion of peripheral blood findings and data from 16 patients on AZT.

Main Results:

  • One-third of bone marrow exams provided specific diagnostic information.
  • Opportunistic infections, particularly Mycobacterium Avium Intracellulare Complex (MAI), were the most frequent specific finding (24%).
  • Non-specific abnormalities included dyserythropoiesis, erythroid hypoplasia, and granulomas; AZT-treated patients showed more pronounced abnormalities.

Conclusions:

  • Bone marrow examination is valuable for diagnosing opportunistic infections and malignancies in advanced HIV disease.
  • Hematological abnormalities in HIV are multifactorial, influenced by viral load, co-infections, and marrow-toxic therapies like AZT.
  • Further research is needed to understand and manage drug-induced bone marrow toxicity in HIV patients.

Related Concept Videos